Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty.
about
Impact of long-term exposure to the tyrosine kinase inhibitor imatinib on the skeleton of growing ratsThe role of stem cell transplantation for chronic myelogenous leukemia in the 21st centuryOutcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort AnalysisPediatric chronic myeloid leukemia is a unique disease that requires a different approachEuropean LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.Leptin modification in chronic myeloid leukemia patients treated with imatinib: An emerging effect of targeted therapy.Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events.Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia.Response dynamics of pediatric patients with chronic myeloid leukemia on imatinib therapy.Kit W-sh Mutation Prevents Cancellous Bone Loss during Calcium Deprivation.Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience.Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years.Adverse effects of imatinib in children with chronic myelogenous leukemia.Relapse of myeloid neoplasm with eosinophilia and PDGFRA rearrangement after imatinib discontinuation in a pediatric patient.Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia.
P2860
Q28548625-B008E2D7-1DBD-4F0D-A7B8-9D24E7303A4BQ35634865-AEDDD782-B9D5-44D7-A02A-D0C2F26C029AQ36928803-3211A356-791B-4616-827E-62920FB150CEQ37025981-DEF3603C-D8AF-4EDB-A2C3-D737B9405EA5Q37026032-FD77D28D-135A-475F-8AF0-B4A3D30E018DQ37362970-48C10A8C-F64F-4929-896B-1A6E5BB82EC1Q38457554-446ACC71-F516-4AA9-8E98-D63BB029E168Q38753313-1A86A920-0D8F-43FA-AA71-7A9D7B4D1DCEQ38813874-1099DC3E-D176-493F-A43C-D3BEE30F4977Q42325011-F88A1942-F231-4496-87C7-76A5B5A65078Q48185992-2E24E143-2A8B-4B59-911D-85CB4866F014Q49101349-63EC0A37-A608-4BC4-A9A0-94ACF45EE064Q51072279-57158653-3B32-487C-AF28-42352A3B4DB7Q51562409-61A8C122-6861-4907-8E99-900DB4533A0EQ54325965-4FE94487-6523-438F-B52A-323D59B78223Q54354157-5BDEC8EF-B208-4871-B8F1-E4B964D68454
P2860
Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Bone metabolism, growth rate a ...... with imatinib during puberty.
@en
Bone metabolism, growth rate a ...... with imatinib during puberty.
@nl
type
label
Bone metabolism, growth rate a ...... with imatinib during puberty.
@en
Bone metabolism, growth rate a ...... with imatinib during puberty.
@nl
prefLabel
Bone metabolism, growth rate a ...... with imatinib during puberty.
@en
Bone metabolism, growth rate a ...... with imatinib during puberty.
@nl
P2093
P2860
P1433
P1476
Bone metabolism, growth rate a ...... with imatinib during puberty.
@en
P2093
Anna Maria Testi
Annalisa De Vellis
Deborah Marzella
Fiorina Giona
Lucio Gnessi
Maria Luisa Moleti
Massimiliano Rea
Stefania Mariani
P2860
P356
10.3324/HAEMATOL.2012.067447
P50
P577
2012-09-14T00:00:00Z